Phase II study of brilacidin for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS).

Trial Profile

Phase II study of brilacidin for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Brilacidin (Primary) ; Brilacidin (Primary)
  • Indications Ulcerative colitis; Ulcerative proctitis; Ulcerative proctosigmoiditis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Innovation Pharmaceuticals
  • Most Recent Events

    • 13 Jul 2017 Results from this trial have been presented at the Drug Discovery & Therapy World Congress, according to an Innovation Pharmaceuticals media release.
    • 13 Jul 2017 Results published in an Innovation Pharmaceuticals media release.
    • 26 Jun 2017 According to an Innovation Pharmaceuticals media release, topline results across all cohorts will be presented at the Drug Discovery & Therapy World Congress in Boston July 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top